“AMI commonly known as heart attack is the commonest cause of death, and even sudden death, in the age group of 45 to 55 years. If treatment is done within one hour effectively, mortality can be reduced from nine percent to three percent, if delay of three to four hours, mortality could be five times higher. Success depends upon prompt detection.

As of now, the conventional methods has low sensitivity in early detection. Therefore, only 15 percent or less patients can receive treatment in the first golden hour. One major drawback is enzymatic detection of acute heart attack. During the heart attack several enzyme levels go up but these does not take place in first four to six hours. Therefore, they are not useful in early detection. The newly developed ‘CardioDetect’ testing system has extremely high sensitivity and is having high specificity for the detection of heart attack.(…)”

Dr. T. V. Ramakrishnan, Professor & Course Co-ordinator,  Dept. of  Accident & Emergency Medicine,  Sri Ramachandra College of Allied Health Sciences,  Sri Ramachandra University,  Chennai

“Very useful cardiac marker to help the emergency physician make a decision and diagnose AMI in patients who present with recent onset of chest pain without typical changes in the ECG ”

Dr. G. Sengottuvelu, Specialist in Interventional Cardiology, APOLLO Hospitals, Chennai

"Measuring h-FABP within the first 4 h of symptoms is superior to cardiac Troponin T to rule out acute myocardial infarction.  A significant clinical advantage can be achieved through the combination approach for many patients with acute chest pain."

“With h-FABP a new highly specific biochemical marker is available for diagnosis of myocardial infarctions that has a high diagnostic sensitivity during the early phase of an infarction compared to other established necrosis markers … The data of our study confirm that it makes sense to use h-FABP as early parameter in the diagnosis of acute coronary syndrome.”

“Such a test is very useful if an emergency doctor cannot safely diagnose the disorders of a patient. With an early test the doctor can start a treatment: he dissolves the clot and reopens the vessel with the highest certainty.”

“We are using the CardioDetect system with great success. It allows us a diagnosis as reliable as we know it from Troponin–but much earlier. Thus, we were able to shorten the time to treatment significantly.”